Research professionals are encouraged to use the contact information on the "Our Team" page of this site to get in touch with members of the NCPC team, or email us at ncpc@northwestern.edu for more information about chemoprevention trials.
​
Information regarding previous publications and findings can be found in the "Completed Trials" section of our website.
Are you A CURRENT or FORMER SMOKER?
Lung cancer, specifically non-small lung cancer (NSCLC), is the leading cause of cancer-related deaths and the second most common cancer in the United States. Former tobacco smokers are at 6-fold higher risk for lung cancer compared to non-smokers. Contrary to common belief, about 60% of individuals at high risk for lung cancer, or those diagnosed in early stages, are overweight (BMI ≥ 25). Ways to help protect high-risk individuals are needed. We are seeing if Metformin Extended Release (ER) has preventive and protective effects that can lower this risk.
ROLE OF METFORMIN IN PREVENTION OF LUNG CANCER IN HIGH-RISK OVERWEIGHT OR OBESE INDIVIDUALS
Principal Investigators:
Sai Yendamuri, MD - Roswell Park Comprehensive Cancer Center
Robert L. Keith, MD - Rocky Mountain Regional VA Medical Center
Stephen Lam, MD - University of British Columbia, BC Cancer Research Centre
Sean A. Jordan, MD, MHS, FACS - University of Tennessee, Knoxville
Metformin ER has been widely used in the US since 1995 and is FDA approved to treat Diabetes Mellitus. Participants who are former smokers will undergo a bronchoscopy, a medical procedure to look into your lungs, and will then be placed into one of two groups based on random chance. Group 1 will receive up to 2000 mg of metformin orally once daily for up to 26 weeks. Group 2 will wait 6 months, undergo another bronchoscopy, and then receive up to 2000 mg of Metformin ER orally once a day for 26 weeks. Participants who are current smokers (group 3) will undergo a bronchoscopy and will then receive up to 2000 mg of metformin orally once daily for up to 26 weeks. Participants in all groups will undergo a final bronchoscopy after finishing their study medication. (Note: people in group 2 will undergo 3 bronchoscopies). This will allow researchers to see if participants taking Metformin ER show changes in their lungs, which may indicate a lower risk of developing cancer.
​
More Information: https://clinicaltrials.gov/ct2/show/study/NCT04931017
​
This study is no longer enrolling new participants. If you are a current participant and have questions about scheduled visits or updates to your medical history or medications, please contact your study team.
Additional Resources
Study Brochure
